Choom Competitors

Abacus Health Products (OTCMKTS:ABAHF) and Choom (OTCMKTS:CHOOF) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Abacus Health Products and Choom, as reported by MarketBeat.

Profitability

This table compares Abacus Health Products and Choom's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Abacus Health Products and Choom's revenue, earnings per share (EPS) and valuation.

Acreage (OTCMKTS:ACRGF) and Choom (OTCMKTS:CHOOF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Valuation and Earnings

This table compares Acreage and Choom's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Acreage and Choom's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Acreage and Choom, as provided by MarketBeat.com.

Acreage presently has a consensus target price of $8.4333, suggesting a potential upside of 204.45%. Given Acreage's higher possible upside, equities analysts plainly believe Acreage is more favorable than Choom.

Summary

Acreage beats Choom on 2 of the 2 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and Choom (OTCMKTS:CHOOF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Valuation and Earnings

This table compares Applied Biosciences and Choom's top-line revenue, earnings per share and valuation.

Profitability

This table compares Applied Biosciences and Choom's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Applied Biosciences and Choom, as reported by MarketBeat.com.

Ayr Strategies (OTCMKTS:AYRSF) and Choom (OTCMKTS:CHOOF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Valuation and Earnings

This table compares Ayr Strategies and Choom's top-line revenue, earnings per share and valuation.

Profitability

This table compares Ayr Strategies and Choom's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Ayr Strategies and Choom, as reported by MarketBeat.com.

Ayr Strategies presently has a consensus target price of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, equities analysts clearly believe Ayr Strategies is more favorable than Choom.

Summary

Ayr Strategies beats Choom on 2 of the 2 factors compared between the two stocks.

Can B (NASDAQ:CANB) and Choom (OTCMKTS:CHOOF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Valuation and Earnings

This table compares Can B and Choom's top-line revenue, earnings per share and valuation.

Profitability

This table compares Can B and Choom's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Can B and Choom, as reported by MarketBeat.com.

Cansortium (OTCMKTS:CNTMF) and Choom (OTCMKTS:CHOOF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Valuation and Earnings

This table compares Cansortium and Choom's top-line revenue, earnings per share and valuation.

Profitability

This table compares Cansortium and Choom's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Cansortium and Choom, as reported by MarketBeat.com.

Cansortium presently has a consensus target price of $1.20, suggesting a potential upside of 39.67%. Given Cansortium's higher probable upside, equities analysts clearly believe Cansortium is more favorable than Choom.

Summary

Cansortium beats Choom on 2 of the 2 factors compared between the two stocks.